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Cerebral edema commonly accompanies brain tumors and contributes to neurologic symptoms. The role of the
interleukin-1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles (SPION–IL-1Ra) was
assessed to analyze its anti-edemal effect and its possible application as a negative contrast enhancing agent for
magnetic resonance imaging (MRI). Rats with intracranial C6 glioma were intravenously administered at various
concentrations of IL-1Ra or SPION–IL-1Ra. Brain peritumoral edema following treatment with receptor antagonist was
assessed with high-field MRI. IL-1Ra administered at later stages of tumor progression significantly reduced
peritumoral edema (as measured by MRI) and prolonged two-fold the life span of comorbid animals in a dose-
dependent manner in comparison to control and corticosteroid-treated animals (P b .001). Synthesized SPION–IL-1Ra
conjugates had theproperties of negative contrast agentwith high coefficients of relaxationefficiency. In vitro studies of
SPION–IL-1Ra nanoparticles demonstrated high intracellular incorporation and absence of toxic influence on C6 cells
and lymphocyte viability andproliferation. Retention of the nanoparticles in the tumor resulted in enhanced hypotensive
T2-weighted images of glioma, proving the application of the conjugates as negative magnetic resonance contrast
agents. Moreover, nanoparticles reduced the peritumoral edema confirming the therapeutic potency of synthesized
conjugates. SPION–IL-1Ra nanoparticles have an anti-edemal effect when administered through a clinically relevant
route in animals with glioma. The SPION–IL-1Ra could be a candidate for theranostic approach in neuro-oncology both
for diagnosis of brain tumors and management of peritumoral edema.
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Peritumoral brain edema is one of the most common complications
of malignant brain tumor growth that contribute to neurologic deficits.
Moreover, as was shown by Schoenegger et al., edema represents an
independent prognostic factor for overall survival of patients with
high-grade glioma [1]. Thus, patients with major edema [N1 cm on
preoperative magnetic resonance imaging (MRI)] had significantly
shorter overall survival compared to patients with minor edema (b1 cm)
[1]. The “gold standard” treatment of peritumoral edema is corticoste-
roid therapy that is associated with numerous serious side effects [2,3].
The large number of complications has led to the discovery of
alternative approaches in the reduction of peritumoral edema in
neuro-oncological patients. Several up-to-date agents were proposed,
including corticotropin releasing factor, cyclooxygenase-2 inhibitors, and
inhibitors of vascular endothelial growth factor (VEGF) [i.e., anti-VEGF
antibodies (bevacizumab) and inhibitors of VEGF receptors (cediranib)]
[4,5]. Implication of anti-angiogenic agents (e.g., bevacizumab) that were
shown to exert anti-edemal effect is limited due to their high cost [6].
Application of the osmotherapy such as diuretic bumetadine was also
shown to decrease the peritumoral edema, thus prolonging the life span of
glioma-bearing animals [7]. Though there is awell-documented reduction
in brain edema, an adverse rebound increase of intracranial pressure is
observed after its withdrawal. Nevertheless, osmotherapy could be applied
as a temporary measure to acutely prevent brain stem compression [8].
An alternative approach could be based on the application of the
interleukin-1 receptor antagonist (IL-1Ra). Previously, it was
demonstrated by Masada et al. that IL-1Ra significantly reduced
brain edema in the experimental model of intracerebral hemorrhage,
probably through reduction of thrombin-induced brain inflammation
[9,10]. In another study by Tehranian et al., IL-1Ra was shown to
modulate expression of pro-inflammatory cytokines (i.e., IL-1 and
tumor necrosis factor alpha [TNFα]) in the model of head injury in
mice [11]. Blockage of IL-1 signaling had a neuroprotective effect and
improved the neurologic recovery after traumatic brain injury.
Moreover, administration of IL-1Ra proved to reduce inflammatory
response in the animal models of brain ischemia [12–14]. In the study
by Pradillo et al., rats following transient (90 minutes) occlusion of
the middle cerebral artery were administered two doses of IL-1Ra
(25 mg/kg, subcutaneously) during reperfusion [13]. Injection of IL-
1Ra significantly reduced infarct volume (as measured by MRI),
microglial activation, neutrophil infiltration, and cytokine levels in
the brain [13]. All the data collected to date indicate that IL-1Ra has a
significant anti-edemal and anti-inflammatory effect in various animal
models and thus might be beneficial in reduction of peritumoral
edema in brain tumors. Moreover, according to several studies, IL-
1Ra also possesses a therapeutic anti-tumor effect [14–16]. Thus, it
was demonstrated by Bar et al. that administration of the antagonist
in the model of fibrosarcoma in mice significantly reduced the tumor
progression and increased the survival rates [14]. One hypothesis for
the inhibition of tumor growth is that IL-1Ra blocks IL-1 receptors in
cancer cells, thus reducing the proliferative and angiogenic effects
of IL-1 [15]. There is also evidence that IL-1Ra downregulates IL-8
that plays a central role in cancer growth [15,17].
In the present study, the anti-edemal effect of IL-1Ra systemically
administered was assessed in the model of intracranial glioma in
rodents. In addition, IL-1Ra activity was analyzed as related to the
glioma progression and overall survival of tumor-bearing animals.
Following analysis of the therapeutic potency of IL-1Ra, a novel
theranostic agent based on superparamagnetic iron oxide nanopar-ticles (SPIONs) was developed. We also report that an engineered
conjugate of SPIONs with IL-1Ra can be applied for diagnosis of
tumors as well as for reduction of peritumoral edema.
Materials and Methods
Preparation and Purification of Recombinant IL-1Ra
IL-1Ra was produced by recombinant gene technology from
Escherichia coli BL21 in solution (99% purity) by State Research Institute
of Highly Pure Biopreparations (St. Petersburg, Russia). Quantitation of
endotoxin was performed using the Limulus amoebocyte lysate assay
(QCL-1000; Cambrex Bio Science, Walkersville, MD). The resulting
endotoxin content was below 0.1 EU/mg IL-1Ra. Biologic activity of
IL-1Ra was assessed in the test of inhibition of induced IL-8 production
byT98 andU118 glioma cells (SupplementaryMaterial 1) and analysis of
mice thymocyte proliferation assay (Supplementary Material 2).
Analysis of the Anti-Edemal Activity of IL-1Ra and Animal
Survival Analysis
Cells. The C6 rat glioma cell line was obtained from the Russian
Cell Culture Collection at the Institute of Cytology, Russian Academy of
Sciences (St. Petersburg, Russia). C6 cells were grown in Dulbecco's
modified Eagle's medium/F12 medium supplemented with 10% FBS,
2 mML-glutamine, and antibiotics (100U/ml penicillinG and0.1 mg/ml
streptomycin). Cells were grown in a CO2 incubator with 6% CO2 and
90% humidity. Viability was determined by 0.4% trypan blue exclusion.
Orthopic model of C6 glioma. Male Wistar rats weighing 250 to
300 gwere purchased from an animal nursery (“Rappolovo”RAMN, St.
Petersburg, Russia). Animals were anesthetized before mounting in a
stereotactic frame (David Kopf Instruments, Tujunda, CA) with 10 mg
of “Zoletyl-100” (tiletamine hydrochloride and zolazepam; “Virbac santé
Animale”, Carros cedex, France) and 0.2 ml of 2% Rometar (xylazinum
hydrochloride; “Bioveta”, Ivanovice na Hané, Czech Republic)
intraperitoneally. C6 glioma cells (1 × 106 cells/ml) resuspended in
10 μl of phosphate-buffered saline (PBS) were injected into the nucl.
caudatus dexter. All animal experiments were approved by the local
ethical committee of the Institute of Cytology (RAS) (St. Petersburg,
Russia) in compliance with the US Department of Health and Human
Services Guide for the Care and Use of Laboratory Animals (1996).
Analysis of IL-1Ra penetration through the blood-tumor barrier. For
assessment of the IL-1Ra retention in the C6 glioma, the protein was
intravenously (i.v.) administered on the 25th day following tumor
inoculation (50 mg/kg). After 24 hours, the animals were sacrificed, and
their brains were extracted and fixed in 10% formaldehyde. IL-1Ra was
revealed with the help of anti–IL-1Ra mice monoclonal antibodies
(Cytokin, St. Petersburg, Russia) and secondary Alexa Fluor 555–
conjugated antibodies (Invitrogen, Carlsbad, CA). Nuclei were stained
withDAPI (4′,6-diamidino-2-phenylindole). Brain sectionswere analyzed
with the help of Leica SP5 confocal microscopy (Leica Microsystems,
Heidelberg, Germany).
Animal survival analysis. To assess the effects of the i.v. infused
IL-1Ra on the survival of the tumor-bearing animals, the experiments
were performed according to the following schedule: the first group of
rats received saline solution (n = 20), the second group of animals was
injected with BSA at 100 mg/kg (n = 20), the third, fourth, and fifth
groups (n = 20) were injected with IL-1Ra at 25, 50, and 100 mg/kg,
respectively, and the sixth group (n = 20) received dexamethasone
(4 mg/kg) i.v. and was used as a positive control. Following intracranial
implantation of the C6 glioma cells on the 15th day, animals were
randomly divided into six groups. Animals received a course of five
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23rd day after the inoculation of the C6 cells. The animal’s survival was
estimated according to the Kaplan-Meier method.
MR assessment of the tumor volume and peritumoral edema. MRI
was used to measure the cerebral edema following treatment with
IL-1Ra. On the 15th day following glioma implantation, animals
were randomly divided into six groups (three animals each) as follows:
control group (infusion of the saline solution), group treated with
dexamethasone (4 mg/kg), BSA-treated groups, and experimental
groups with i.v. administration of IL-1Ra at 25, 50, and 100 mg/kg,
respectively. Twenty-four hours after injection, animals were assessed
with multiple MRI modalities. MR sequences were obtained at the
following regimens: TurboRARE-T2, RARE-T1, FLASH, multi-slice
multi-echo (MSME), and diffusion-weighted image (DWI). Tumor
volume on T1-weighted and T2-weighted MR scans was calculated by
measuring the cross-sectional areas on each MR slice and multiplying
their sum by the slice thickness. Peritumoral edema was defined as a
region of increased T2 signal intensity on the tumor margin. In the
perifocal lesion area, the apparent diffusion coefficient (ADC) value was
assessed. ADC values were calculated according to the following
formula: ADC = −1(1/b)ln(S/S0), where S and S0 were the signal
intensities in the region of interest (ROI) that was obtained with various
gradient factors (b values of 0 and 1000 s/mm2). The ROI was placed
in the C6 glioma and normal brain area on the ADC map. Each ROI
was positioned twice with a change of location, and ADC values were
averaged. ADC values of the animals from the control group and those
of the animals treated with BSA, dexamethasone, and IL-1Ra at 25, 50,
and 100 mg/kg were compared. Three animals were allocated for each
group. ADC values were obtained on the 14th, 20th, 25th, and 30th
day following C6 glioma inoculation.
Synthesis of Magnetic Nanoparticles Conjugated with IL-1Ra
Recombinant IL-1Ra was conjugated with SPIONs as described
earlier [15]. Briefly, SPIONs were prepared from iron salt solutions
by co-precipitation in alkaline media at 80°C. FeSO4 and FeCl3 at an
Fe2+/Fe3+ ratio of 1:2 were dissolved in water with the addition of
CsCl. Magnetite precipitation was induced by titration with an
NH4OH solution in an inert atmosphere under vigorous stirring in a
100-ml reactor. The precipitate was collected by a permanent magnet.
To prevent sedimentation, low molecular weight dextran (MW 10
kDa; Sigma, St. Louis, MO) was added to the dispersion during the
process of ultrasound application. The prepared stock solution of
nanoparticles was washed and separated into fractions by centrifu-
gation and microfiltration using 0.2-μm pore membranes (Millipore,
Billerica, MA). The Fe content in the suspension was controlled by
UV absorption of the thiocyanate-Fe(+3) complex at λ = 480 nm.
For conjugation with IL-1Ra, the dextran coating on the magnetic
nanoparticles was cross-linked with epichlorohydrin and aminated.
Magnetic nanoparticles were suspended in a phosphate-buffered
solution of IL-1Ra (60 μg/ml). The conjugation reaction was carried
out at 20°C with shaking for 1 hour. Soluble carbodiimide dextran
was activated by water and coupled to the carboxyl groups of IL-1Ra,
producing a magnetic conjugate. The specific immune activity of the
synthesized SPION–IL-1Ra conjugates was estimated by a magnetic
relaxation switch assay [16,17]. The Fe content in the magnetic IL-
1Ra conjugate samples was analyzed by spectrophotometry of the
thiocyanate-Fe(+3) complex, prepared by HNO3 dissolution. The
IL-1Ra content in conjugate samples was measured using a human
IL-1Ra ELISA kit (Protein Contour, St. Petersburg, Russia).The particle size and size distribution of SPIONs and its conjugates
were studied by transmission electron microscopy (TEM) using a
JEOL-2000 microscope (JEOL, Akishima, Tokyo, Japan) and
dynamic light scattering (DLS) (Supplementary Material 3) using a
Malvern instrument. The hydrodynamic size and electrophoretic
properties were measured on Zetasizer Nano (Malvern,Worcestershire,
United Kingdom). NMR spectra and magnetic relaxation times, i.e.,
T1, T2, and T2, were measured using CXP-300, an nuclear magnetic
resonance (NMR) spectrometer (Bruker, Billerica, MA), with a
magnetic field of 7.1 T. To estimate the magnetic relaxation times,
the inversion recovery and Carr-Purcell-Meiboom-Gill impulse
sequences were applied. Proton relaxation times were studied as a
function of the magnetic IL-1Ra conjugate concentration in a buffered
solution. The coefficients of relaxation efficiency, i.e., R1, R2, and R2
(relaxivity), were determined from the slopes of the concentration plots.
Assessment of C6 Cells and Lymphocyte Uptake of
SPION–IL-1Ra
In the series of in vitro experiments, the IL-1Ra conjugates were
added to the C6 glioma cell culture for 6, 12, and 24 hours (Fe
concentration of 150 μg/ml). Following incubation, cells were
washed, fixed, and analyzed with the help of confocal microscopy
on a Leica DM IRBE microscope (Leica Microsystems) by reflecting
laser scanning for SPION–IL-1Ra distribution inside the C6 cells.
The uptake of the conjugates was also analyzed in rat lymphocytes.
Cells were isolated from the peripheral blood mononuclear cells
obtained by Ficoll density gradient centrifugation. Additionally, cells
were purified from monocytes by adherence as described elsewhere
[22]. Following purification, cells were incubated with SPION or
SPION–IL-1Ra for 6, 12, and 24 hours and assessed for distribution
of nanoparticles with the help of confocal microscopy, as was
described earlier. The localization of the conjugates in the cells was
assessed by TEM. Briefly, following incubation with SPION or
SPION–IL-1Ra conjugates for 24 hours, cells were detached with
trypsin/EDTA from the culture plate, fixed in 2.5% glutaraldehyde in
0.1 M cacodylate buffer, pH 7.4, for 1 hour at 4°C, postfixed in 1%
aqueous OsO4 for 1 hour, dehydrated, and embedded in Epon and
Araldite, and then sectionedwith a diamond knife on an LKBultratome.
Ultrathin sections were collected on finemesh copper or nickel grids and
stained with uranyl acetate and lead citrate for examination with Zeiss
Libra 120 electron microscope operated at 80 kV.
Assessment of Tumor Targeting with SPION–IL-1Ra Conjugates
To assess the accumulation of IL-1Ra conjugated with SPION
in C6 gliomas, animals were randomly divided into three groups
(three animals each) on the 25th day after C6 cell administration: 1)
i.v. injection of PBS (control group); 2) i.v. injection of SPION
(300 μl, 0.3 mg/kg) for 24 hours; 3) i.v. injection of SPION–IL-1Ra
conjugates (300 μl, 0.3 mg/kg) for 24 hours. Assessment was
performed using a high-field 11-T MRI scanner (Bruker) with a
custom rat coil. High-resolution anatomic T2-weighted scans [repetition
time (TR)/echo time (TE) 4200/36 milliseconds, flip angle 180°, slice
thickness 1.0 mm, interslice distance 1.2 mm, field of vision 2.5 ×
2.5 cm, matrix 256 × 256, in total 20 slices] were performed in the
coronal plane. Additionally, we performed T1-weighted scans (TR/TE
1500/7.5 milliseconds, flip angle 180°, slice thickness 1.0 mm, field of
vision 2.5 × 2.5 cm, matrix 256 × 256) and FLASH scans (TR/TE 350/
5.4 milliseconds, flip angle 40°, slice thickness 1.0 mm, 2.5 × 2.5 cm,
matrix 256 × 256) in the coronal plane. For an estimation of the
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sequences. The obtained images were analyzed using Analyze software
(AnalyzeDirect, Inc, Overland Park, KS). The MSME images were used
to generateT2maps over the tumor region. For a calculation of the tumor
contrast enhancement on the T2 maps, we applied the software package
Paravision 3.1 (Bruker BioSpin GmbH, Rheinstetten, Germany). We
displayed the histogram and calculated the mean and SD of theT2 values
of the tumor. Retention of the IL-1Ra conjugates in the tumor was
further confirmed with the histologic analysis of the tumor samples.
Following injection of the conjugates, the rats were sacrificed, and tumors
were extracted and fixed overnight in 10% formalin. Tissues were then
embedded in Tissue-Tek and stored at −80°C. Sections (5-7 μm thick)
prepared from these blocks were mounted on SuperFrost Plus slides
(Fischer Scientific, Hampton, NH) and used for the detection of
magnetic conjugates through confocal microscopy. Sections were
additionally stained with DAPI. Fluorescence images were obtained
using a Leica TCS SP5 confocal system. SPIONs or SPION–IL-1Ra
conjugates were detected by reflecting laser scanning with laser excitation
at 488 nm (Ar/Kr). Nuclei were detected using a diode laser (405 nm).
For survival analysis, animals were randomly divided on the 14th day in
five groups (10 rats each) as follows: control, BSA treated, dexamethasone
treated (4 mg/kg), SPION treated, and SPION–IL-Ra treated at 1.25 and
2.5 mg/kg of total IL-1Ra per treatment course.
Statistical Analysis
Kaplan-Meier survival curves were plotted for the five groups of
animals treated with saline solution, dexamethasone, or IL-1Ra at
various concentrations. Two-tailed Student’s t tests were used to
evaluate the differences between control and experimental groups. All
data were analyzed with Statistica Version 9.2 for Windows and with
the R statistical computing program. P values of b .05 were considered
statistically significant for all tests.Figure 1. Confocal microscopy of the C6 glioma following i.
v. administration of the IL-1Ra. Nuclei were stained with DAPI (blue). IL-
1Ra was detected with monoclonal antibodies conjugated with Alexa
Fluor 555 (red). Scale bar, 75 μm.Results
IL-1Ra Penetrates the Blood-Tumor Barrier and Exerts
an Anti-Edemal Activity
Following i.v. injection of IL-1Ra, the accumulation of protein was
assessed in the C6 glioma with the help of confocal microscopy
(Figure 1). Twenty-four hours after infusion, IL-1Ra could be detected
in the glioblastoma cells throughout the tumor. High magnification
demonstrated the cytoplasmic localization of the IL-1Ra. Tumor
retention of the antagonist had a significant influence on the
peritumoral brain edema. The mean ADC value of the C6 glioma
from the control group was 2.28 ± 0.11 × 10−3 mm2/s (Supplementary
Material 4). The mean ADC value did not significantly change in all
studies with a slight increase up to day 30 (Figure 2). Application of the
BSA as a control protein also did not influence the ADC parameter,
equaling on the 30th day 2.77 ± 0.08 × 10−3 mm2/s. Intravenous
injection of the dexamethasone resulted in the decrease of the ADC
value on the 20th day in comparison to the control and BSA-treated
animals (P b .001). Thus, on the 20th and 25th days, the ADC values
were 1.77 ± 0.08 × 10−3 and 1.44 ± 0.09 × 10−3 mm2/s, respectively.
Intriguingly, following cessation of dexamethasone treatment on the
23rd day, on the 30th day the ADC values started to increase and were
2.75 ± 0.23 × 10−3 mm2/s. The subsequently obtained ADCmaps for
the treated animals also proved the dexamethasone effect (Figure 3A).
When recombinant IL-1Ra was applied at 25 mg/kg on the 20th day,
the decrease of the ADC value was comparable to that of thedexamethasone-treated group—1.72 ± 0.05 × 10−3 mm2/s. Further,
IL-1Ra therapy resulted in the gradual decrease of the ADC value. On
the 30th day, the anti-edemal effect was still observed—1.40 ± 0.05 ×
10−3 mm2/s in comparison to the dexamethasone-treated group (P b
.001). A statistically significant difference in ADC values was observed
when the IL-1Ra at 50 and 100 mg/kg was administered. There was a
significant decrease of edema in the glioma tissue as well as of peritumoral
edema (Figure 3A). Thus, at 20th day, the ADC values were considerably
lower than in dexamethasone- and IL-1Ra (25 mg/kg)–treated groups,
equaling 1.07 ± 0.09 × 10−3 and 0.69 ± 0.10 × 10−3 mm2/s, respectively
(P b .001). The ADC values continued to be low for all periods of
treatment and, at 30th day, were still significantly lower in comparison
to other groups—0.68 ± 0.03 × 10−3 (for 50 mg/kg) and 0.57 ± 0.04 ×
10−3 (for 100 mg/kg) mm2/s, respectively.
Intravenous Administration of IL-1Ra Reduces the TumorGrowth
and Increases the Overall Survival of Tumor-Bearing Rats
In vivo studies showed the feasibility and safety of systemic delivery of
the antagonist. We did not observe any side effects (i.e., behavioural
changes) after infusion of IL-1Ra. According to the MR data on the
14th day following tumor inoculation, the mean tumor volume in the
Figure 2. Side-by-side boxplots of ADC. ADC was calculated for the five experimental groups and for the control group on days 14, 20, 25,
and 30 following C6 glioma cell inoculation.
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The exponential tumor growth was observed in control and
BSA-treated groups, and at day 28, the tumor was 547.21 ± 64.29
and 590.19 ± 21.88 mm3, respectively (Figure 3B). Dexamethasone
administration resulted in the decrease of the tumor progression. Thus,
on the 28th day, the glioma volume was 342.46 ± 31.65 mm3, and
only after the cessation of the corticosteroid therapy did the tumor
growth continue to increase, equaling on the 42nd day 588.52 ±
13.83 mm3 (P b .001). The effect of IL-1Ra infusion at 25 mg/kg was
comparable to that of dexamethasonewith amean tumor volume on the
28th day of 350.53 ± 11.29 mm3. Further increase of antagonist
concentration resulted in significant delay of tumor progression.
Following the end of IL-1Ra infusions on the 23rd day, the delay of the
glioma growth was still obvious, constituting 396.43 ± 13.48 (IL-1Ra,
50 mg/kg) and 338.20 ± 6.65 (100 mg/kg) mm3.
Intravenous delivery of the IL-1Ra prolonged the life span of rats in
the experimental groups in a dose-dependent manner (Figure 3C).
Accordingly, in the IL-1Ra–treated group at 50 mg/kg, the survival was
increased two-fold in comparison to the control and BSA-treated groups,
equaling 41.5 ± 11.9, 23.9 ± 3.4 and 23.2 ± 3.4 days, respectively (P b
.001). Further increase of the concentration of the infused IL-1Ra to
100 mg/kg resulted in elevation of the survival up to 51.3 ± 15.6 days
(Pb .001). Application of dexamethasone as a positive control resulted in
the slight but statistically significant increase in rats’ survival compared tocontrol—36.9 ± 8.2 days (P b .001). The efficacy of the corticosteroid
therapy was comparable to the injection of IL-1Ra at 25 mg/kg.
However, application of the antagonist at higher doses (i.e., 50 and
100 mg/kg) demonstrated an increase in animals’ survival that
dramatically exceeded the survival in the corticosteroid-treated group.
Synthesized SPION–IL-1Ra Conjugates Exert the Properties of
the Negative MR Contrast Agent
The prepared magnetic conjugates of IL-1Ra appeared to have the
typical characteristics of SPIONs known for different magnetic
nanodispersions of various compositions. According to DLS measure-
ments, the conjugate solutions have a colloidal structure consisting of
iron oxide nanoparticles coated by dextran with a coupled receptor
antagonist. The measured hydrodynamic radius of non-conjugated
SPIONs was 37.9 nm (Figure 4A). The IL-1Ra conjugation increased
the mean size of the nanoparticles to 43.1 nm. The measured zeta
potential of the SPION–IL-1Ra was 13.8 mV (Figure 4B). The
presence of IL-1Ra in the nanoparticles was assessed with the DLS assay
(Figure 4C ). Addition of the anti-IL-1Ra monoclonal antibodies
resulted in a significant increase of the nanoparticles’ size that was not
observed if control isotype IgG antibodies were applied. SPION–
IL-1Ra conjugate solutions exhibited the properties of negative contrast
enhancement as was demonstrated by NMR data (Figure 5). Magnetic
relaxation study of SPION–IL-1Ra nanoparticles proves the strong
Figure 3. Anti-edemal activity of recombinant IL-1Ra and animal survival analysis. (A) MRI of the C6 glioma at day 25 for the animals from
control and treatedwith BSA, dexamethasone (DEX), and IL-1Ra at 25, 50, and 100 mg/kg.MRscanswere obtained at RARE-T1, TurboRARE-
T2, andDWI regimens. Additionally for eachanimal, theADCmapwascalculated. (B) Tumor volumegrowthdynamics (mm3) for animals from
five experimental groups and control group. (C) Kaplan-Meier survival curves for control and experimental groups.
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oxide magnetic core in dispersion. The magnetic relaxation behavior
had a dose-dependent character. The decrease of magnetic relaxation
times T1, T2, and T2 was in linear dependence on the iron content in
suspension measured by UV absorbance of thiosulfate coordination
complex. The values of relaxation efficiency were calculated as derivative
coefficients of linear plots of concentration dependences.
Accumulation of the SPION–IL-1Ra Nanoparticles in C6 Cells
and Lymphocytes
Toxicity analysis that included C6 proliferation assessment by
exclusion of the trypan blue and dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, measured by relative
viability, clearly demonstrated the absence of toxic effects of SPIONs
or SPION–IL-1Ra conjugates (at the range of Fe concentrations from
150 to 350 μg/ml). The cell viability did not differ at any time points of
incubation (1, 3, 12, and 24 hours) with SPIONs or SPION–IL-1Ra
nanocarriers, and it was not different from control cells. Further, the
incorporation of the nanoparticles into the C6 cells was assessed(Figure 6A). Following 24 hours of incubation with SPIONs,
the cytoplasmic incorporation of the particles by glioma cells was
demonstrated. When SPION–IL-1Ra conjugates were applied, the
amount of the included nanoparticles was significantly higher in
comparison to the non-modified SPION. Subsequent addition of
blockingmonoclonal anti–IL-1R antibodies resulted in the reduction of
the SPION–IL-1Ra being taken up by C6 cells, which indicates
the possible mechanism of receptor-mediated endocytosis. Further
immunocytochemistry demonstrated that SPION–IL-1Ra conjugates
were co-localized with IL-1R in the endosome-like structures in
the cytoplasm (Figure 6B). The confocal microscopy analyses of the
SPIONs or SPION–IL-1Ra conjugates with rat lymphocytes clearly
demonstrated the receptor-mediated mechanism of antagonist incor-
poration into the cells (Figure 6, C and D).
Retention of SPION–IL-1Ra in the Tumor Decreases the
Peritumoral Edema and Prolongs the Life Span of Animals
All i.v. injections of SPION–IL-1Ra or SPIONs were well
tolerated by the rats. We did not observe any side effects. The C6
38 IL-1Ra in Treatment of Peritumoral Brain Edema Shevtsov et al. Neoplasia Vol. 17, No. 1, 2015glioma presented as hypotensive or isotensive on the T1-weighted
images and hypertensive on the T2-weighted scans (Figure 7A).
When non-conjugated SPIONs following 24 hours were applied,
the retention of the nanoparticles was observed in the brain tumor
as hypotensive zones on T2-weighted images with a slight change
in the T2 values. When SPION–IL-1Ra conjugates were applied, a
significant decrease in the T2 signal in the zone of the tumor after
24 hours of injection in comparison to that of non-modified SPIONs
or control non-treated animal was observed (P b .001). Antagonist
magnetic conjugates accumulated throughout the glioma and presented
as hypotense zones on theT2-weighted images. CorrespondingT2 maps
of the treated tumor calculated from the MSME images demonstrated
decreasedT2 values. Confocal microscopy analysis of the tumor sections
in the reflecting laser scanning confirmed the accumulation of the
SPION–IL-1Ra conjugates in the C6 tumor (Figure 7B). Nanoparticles
accumulated in the cytoplasm of the cells surrounding the nucleus.
According to animal survival analysis, infusions of the IL-1Ra conjugates
(of a total of 2.5 mg/kg IL-1Ra) also prolonged the survival of animals in
comparison to the control and SPION-treated groups, amounting to
21.4 ± 4.1, 21.7 ± 3.7, and 41.5 ± 11.32 days, respectively (P b .001)
(Figure 7C). Subsequent diffusion-weighted imaging and ADC maps
demonstrated that tumor retention of the SPION–IL-1Ra conjugates
resulted in the decrease of the peritumoral edema in comparison to the
non-conjugated SPIONs (Figure 7D).
Discussion
Nanomedicine based on iron oxide magnetic nanoparticles function-
alized with various bioligands has brought a paradigm shift in the
diagnosis and treatment of malignant brain tumors [23,24]. Due to
their unique properties, functionalized magnetic particles could be
used both as negative MR contrast agents for tumor detection and
carriers for tumor-targeted drug delivery [25]. This approach was
tested for numerous combinations of bioligands and their receptorsFigure 4.Magnetic relaxation rates R2
*, R2, and R1 of water protons in
the Fe concentration at 20°C.that are overexpressed in gliomas including Pep-1, a specific ligand for
IL-13Rα2, antibodies for epidermal growth factor receptor deletion
mutant, epidermal growth factor receptor vIII, Hsp70 for CD40
receptor, F3 peptide for nucleolin, and many others [19-21,26–28].
For the present study, a recombinant receptor antagonist for IL-1
(IL-1Ra) that was conjugated with magnetic nanoparticles (SPION–
IL-1Ra) was applied. IL-1 isoforms (IL-1α and IL-1β) play roles in tumor
progression, angiogenesis, and metastasis either directly or indirectly
through induction of various cytokines [29]. Moreover, IL-1 also
promotes myeloid-derived suppressor cells and M2-type macrophages
that exert immunosuppression in the tumor site [30,31]. Thus,
application of IL-1Ra might not only reduce tumor-induced edema
but also influence the glioma growth. According to our data, we observed
a dramatic accumulation of the recombinant IL-1Ra in the glioma tissue
if i.v. administered (Figure 3). Previously, the IL-1Ra pharmacokinetics,
biodistribution, and metabolism were studied using [18F]–IL-1Ra and
positron emission tomography (PET) imaging in rats [32]. The results of
protein uptake exhibited slower pharmacokinetics in the normal brain
due to the presence of the blood-brain barrier [32]. The retention of
receptor antagonist in the glioma could be explained by the disrupted
blood-brain barrier that characterizes the growth of malignant brain
tumors [18,33–36].
In our studies, it was shown for the first time that recombinant IL-1Ra
has a significant anti-edemal effect in the experimental brain tumor model
(Figures 2 and 3). Systemic administration of IL-1Ra dramatically reduced
the peritumoral edema in a dose-dependentmanner. For analysis of edema,
we applied the ADC that is used as a sensitive method for assessment of
treatment response in neuro-oncology [37]. Intriguingly, we observed a
decrease in ADCs for IL-1Ra–treated groups in comparison to control,
BSA-treated, and dexamethasone-treated groups (Figure 2). Thus, on the
30th day following tumor inoculation, the ADC coefficient for the control
group was 2.62 ± 0.08, while for IL-1Ra (100 mg/kg), it was 0.57 ± 0.04
(P b .001). The reduction of tumor-induced edema on DWIs and ADCSPIONs and SPION–IL-1Ra conjugate dispersion in dependence on
Figure 5. Characterization of the synthesized SPION–IL-1Ra conjugates. (A) Hydrodynamic size (r.nm) of the SPIONs and SPION–IL-1Ra
nanoparticles. (B) Zeta potential for the SPION–IL-1Ra conjugates. (C) DLS assay for the SPION–IL-1Ra particles incubated with isotype
IgG antibodies or monoclonal anti–IL-1Ra antibodies for 4 hours.
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(e.g., bevacizumab, endostatin, and cediranib) [38–40].Moreover, IL-1Ra
exhibited a significant effect on the tumor growth dynamics (as assessed by
MRI) and survival rates (Figure 3B). Our results are reminiscent of
previously published data when IL-1Ra was shown to inhibit the
development and growth of metastases in mouse B16 melanoma,
human cutaneous melanoma xenografts, and uveal melanoma [41–44].
Following assessment of IL-1Ra, we analyzed the theranostic activity of
the SPION–IL-1Ra conjugate. The parameters of R1,R2, andR2
* relaxivity
for synthesized conjugates were comparable to that of T2-negative MR
contrast agents (Figure 5). As was expected, magnetic nanoparticles were
incorporated inside the C6 glioma cells as well as the rats’ lymphocytes
(Figure 6). The uptake of nanoparticles did not exert the toxic effects on
the cells, as was demonstrated with the help of MTT and trypan blue
exclusion methods. The i.v. injection of the SPION–IL-1Ra resulted in
the retention of the particles in the glioma tissue that was observed atT2-weighted images and subsequent histologic assay (Figure 7).
Previously, it was shown that functionalized particles may penetrate the
brain-tumor barrier, enhancing the T2-weighted MR scans of the brain
tumors [19,27,45,46]. Incorporation of magnetic conjugates was
displayed as obvious dark regions in the glioma on T2 scans in
comparison to baseline images (on TurobRARE-T2 and FLASH
regimens; Figure 7A). Application of IL-1Ra increased the tumor
retention of the conjugates compared to non-conjugated SPIONs
probably due to the IL-1 receptor–mediated targeted delivery of the
particles (Figure 6).Moreover, synthesized SPION–IL-1Ra also exerted a
therapeutic potential. Thus, accumulation of conjugates resulted in the
reduction of the peritumoral edema (as shown on ADCmaps) compared
to the non-conjugated magnetic particles. Significantly, magnetic
conjugates demonstrated biologic anti-edemal therapy at significantly
lower concentrations of receptor antagonist (i.e., 2.5 mg/kg) in
comparison to the administration of purified protein (when the effect
Figure 6. Interaction of the magnetic conjugates of IL-1Ra with C6 cells or lymphocytes. (A) Confocal microscopy images of the C6 cells
following 24 hours of incubation with PBS, SPIONs (150 μg/ml), and SPION–IL-1Ra conjugates (150 μg/ml). Nuclei were stained with
DAPI (blue). Magnetic nanoparticles were detected by reflecting laser scanning at 488 nm (green). Scale bar, 25 μm. For analysis of the
receptor-mediated endocytosis, C6 cells were also incubated with anti–IL-1R monoclonal antibodies. (B) TEM of the C6 cell incubated for
24 hours with SPION–IL-1Ra conjugates. Electron dense nanoparticles were present in the cytoplasm of cells in the endosome-like
structures (blue solid arrow). Receptors for IL-1 were detected with monoclonal anti–IL-1R antibodies (red solid arrow). Scale bar, 500 nm.
(C) Confocal microscopy images of the rat lymphocytes following 24 hours of incubation with PBS, SPIONs (150 μg/ml), and SPION–IL-1Ra
conjugates (150 μg/ml). Nuclei were stained with DAPI (blue). Magnetic nanoparticles are represented in the cytoplasm as green dots. Scale
bar, 25 μm. For analysis of the receptor-mediated endocytosis, C6 cells were also incubatedwith anti–IL-1Rmonoclonal antibodies. (D) TEM
of the lymphocyte incubated for 24 hours with SPION–IL-1Ra conjugates (blue arrows). Receptors for IL-1 were detected with monoclonal
anti–IL-1R antibodies (red arrows). Scale bar, 500 nm.
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Presumably, covalent binding of protein to the nanoparticles may
increase the biologic activity of the protein, probably due to molecular
interaction between the nanomaterial and the biomolecule [47,48].
Correspondingly, it was shown by Singh et al. that conjugation of the
Gαi1 subunit (of heterotrimeric G-proteins) to gold nanoparticles
accelerated its GTPase activity five-fold [47]. In addition, the
phenomenon of enhanced permeability and retention allows themagnetic
nanoparticles to enter the tumor interstitial space, whereas the suppressed
lymphatic filtration allows them to stay there [49]. Presumably due to theenhanced permeability and retention effect, SPION–IL-1Ra conjugates
remain longer in the glioma tissue than the IL-1Ra protein, thus
enhancing the potency of the antagonist in the tumor.
The tumor retention of SPION–IL-1Ra also influenced the
survival of the tumor-bearing rats (Figure 7C ). Thus, we observed a
nearly two-fold increase in the life span of those rats treated with
SPION–IL-1Ra in comparison to control animals (P b .001).
Recombinant IL-1Ra was successfully applied for management of
experimental peritumoral edema in the C6 glioma model. The systemic
administration of IL-1Ra significantly reduced the edema and exceeded
Figure 7. C6 glioma targeting with SPION–IL-1Ra conjugates. (A) MRI of the C6 glioma 24 hours following i.v. treatment with SPIONs
or SPION–IL-1Ra conjugates. MR scans were obtained at RARE-T1, TurboRARE-T2, FLASH, and MSME regimens. Retention of the
magnetic nanoparticles is presented as hypotensive zones at T2-weighted images and in the regimen of the gradient echo (red arrows).
(B) Confocal microscopy of the C6 glioma sections. Nanoparticles were detected by reflecting laser scanning (green) and nuclei were
stained with DAPI (blue). Scale bar, 75 μm. (C) Kaplan-Meier survival curves for the control group and animals treated with BSA,
dexamethasone, and SPION–IL-1Ra conjugates at 1.25 and 2.5 mg/kg of IL-1Ra. (D) DWIs and the corresponding ADC maps for the
animals treated with SPION or SPION–IL-1Ra conjugates.
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promoted the survival of animals with reduction of tumor growth rates.
Synthesized conjugates of IL-1Ra with superparamagnetic nanoparticles
improved the tumor retention of the protein without compromising its
biologic activity. The encouraging results of theranostic application of
SPION–IL-1Ra conjugates for tumor MR visualization and anti-edemal
therapy warrant further study with a view to clinical application of the
conjugates in neuro-oncology.
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